Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service SI joint fusion cases in Oregon: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 22% on average (44 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 101 | 50% |
| 2020 | 1 | 72 | 51% |
| 2021 | 1 | 128 | 53% |
| 2022 | 3 | 135 | 56% |
| 2023 | 2 | 135 | 58% |
| 2024 | 2 | 137 | 59% |
| 2025 from claims | – | 211 172–249 | 59% |
| 2026 forecast | – | 234 185–296 | 58% |
| 2027 forecast | – | 255 192–340 | 58% |
| 2028 forecast | – | 278 201–388 | 58% |
| 2029 forecast | – | 304 211–441 | 58% |
| 2030 forecast | – | 331 222–499 | 58% |
Minimally invasive and open sacroiliac joint fusion. Professional codes (what the surgeon bills): CPT 27279, 27280, 0775T, 27278.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Oregon; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 20% inpatient hospital, 40% hospital outpatient, 40% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 23 | 889+14%/yr | +14%/yr | 0.2 | 32% | 970 in 2030+1.5%/yr |
| Colorado | 9 | 399+23%/yr | +23%/yr | 0.7 | 11% | 680 in 2030+9.4%/yr |
| Arizona | 5 | 375+29%/yr | +29%/yr | 0.5 | 67% | 980 in 2030+17%/yr |
| Washington | 4 | 212+5.3%/yr | +5.3%/yr | 0.2 | 100% | 100 in 2030−12%/yr |
| Idaho | 2 | 134+49%/yr | +49%/yr | 0.6 | 0% | 220 in 2030+8.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 37 | 1,701−5.1%/yr | −5.1%/yr | 3.91.3× | 38% | 1,710 in 20300%/yr |
| Lumbar fusion | 23 | 1,034−3.1%/yr | −3.1%/yr | 2.40.8× | 2% | 960 in 2030−1.2%/yr |
| Cervical fusion & disc arthroplasty | 11 | 618−4.2%/yr | −4.2%/yr | 1.41.1× | 25% | 700 in 2030+2%/yr |
| Kyphoplasty & vertebroplasty | 0 | 174+0.3%/yr | +0.3%/yr | 0.40.4× | 100% | 300 in 2030+9.6%/yr |
SI joint fusion in every state, and its device makers · Every procedure market in Oregon · Every state · Compare with California
SI-BONE leads with 91% of company spending on these surgeons in 2025, −9 pts on 2024.
In 2025, 3 companies reported engagement with Oregon’s surgeons worth $84K in consulting, speaking, meals and travel tied to these products, about $42K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 6 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.